Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies
The interleukin 17 (IL-17) family, a subset of cytokines consisting of IL-17A-F, plays crucial roles in host defence against microbial organisms and the development of inflammatory diseases, including psoriasis (PsO), axial spondyloarthritis (axSpA), and psoriatic arthritis (PsA). IL-17A is the sign...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/12/10305 |
| _version_ | 1797594287201845248 |
|---|---|
| author | Guillermo Sánchez-Rodríguez Lluís Puig |
| author_facet | Guillermo Sánchez-Rodríguez Lluís Puig |
| author_sort | Guillermo Sánchez-Rodríguez |
| collection | DOAJ |
| description | The interleukin 17 (IL-17) family, a subset of cytokines consisting of IL-17A-F, plays crucial roles in host defence against microbial organisms and the development of inflammatory diseases, including psoriasis (PsO), axial spondyloarthritis (axSpA), and psoriatic arthritis (PsA). IL-17A is the signature cytokine produced by T helper 17 (Th17) cells and is considered the most biologically active form. The pathogenetic involvement of IL-17A in these conditions has been confirmed, and its blockade with biological agents has provided a highly effective therapeutical approach. IL-17F is also overexpressed in the skin and synovial tissues of patients with these diseases, and recent studies suggest its involvement in promoting inflammation and tissue damage in axSpA and PsA. The simultaneous targeting of IL-17A and IL-17F by dual inhibitors and bispecific antibodies may improve the management of Pso, PsA, and axSpA, as demonstrated in the pivotal studies of dual specific antibodies such as bimekizumab. The present review focuses on the role of IL-17F and its therapeutic blockade in axSpA and PsA. |
| first_indexed | 2024-03-11T02:20:32Z |
| format | Article |
| id | doaj.art-90a951a470ee414aafb998d9fe244f4c |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-11T02:20:32Z |
| publishDate | 2023-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-90a951a470ee414aafb998d9fe244f4c2023-11-18T10:51:38ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-06-0124121030510.3390/ijms241210305Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and SpondyloarthropathiesGuillermo Sánchez-Rodríguez0Lluís Puig1Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Carrer de Sant Quintí, 89, 08041 Barcelona, SpainDepartment of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Carrer de Sant Quintí, 89, 08041 Barcelona, SpainThe interleukin 17 (IL-17) family, a subset of cytokines consisting of IL-17A-F, plays crucial roles in host defence against microbial organisms and the development of inflammatory diseases, including psoriasis (PsO), axial spondyloarthritis (axSpA), and psoriatic arthritis (PsA). IL-17A is the signature cytokine produced by T helper 17 (Th17) cells and is considered the most biologically active form. The pathogenetic involvement of IL-17A in these conditions has been confirmed, and its blockade with biological agents has provided a highly effective therapeutical approach. IL-17F is also overexpressed in the skin and synovial tissues of patients with these diseases, and recent studies suggest its involvement in promoting inflammation and tissue damage in axSpA and PsA. The simultaneous targeting of IL-17A and IL-17F by dual inhibitors and bispecific antibodies may improve the management of Pso, PsA, and axSpA, as demonstrated in the pivotal studies of dual specific antibodies such as bimekizumab. The present review focuses on the role of IL-17F and its therapeutic blockade in axSpA and PsA.https://www.mdpi.com/1422-0067/24/12/10305psoriatic arthritisaxial spondyloarthritisinterleukin 17Fpsoriasisbimekizumabsonelokimab |
| spellingShingle | Guillermo Sánchez-Rodríguez Lluís Puig Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies International Journal of Molecular Sciences psoriatic arthritis axial spondyloarthritis interleukin 17F psoriasis bimekizumab sonelokimab |
| title | Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies |
| title_full | Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies |
| title_fullStr | Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies |
| title_full_unstemmed | Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies |
| title_short | Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies |
| title_sort | pathogenic role of il 17 and therapeutic targeting of il 17f in psoriatic arthritis and spondyloarthropathies |
| topic | psoriatic arthritis axial spondyloarthritis interleukin 17F psoriasis bimekizumab sonelokimab |
| url | https://www.mdpi.com/1422-0067/24/12/10305 |
| work_keys_str_mv | AT guillermosanchezrodriguez pathogenicroleofil17andtherapeutictargetingofil17finpsoriaticarthritisandspondyloarthropathies AT lluispuig pathogenicroleofil17andtherapeutictargetingofil17finpsoriaticarthritisandspondyloarthropathies |